Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers

Peter Izmirly, Mimi Kim, Deborah M. Friedman, Nathalie Costedoat-Chalumeau, Robert Clancy, Joshua A. Copel, Colin K.L. Phoon, Bettina F. Cuneo, Rebecca E. Cohen, Kimberly Robins, Mala Masson, Benjamin J. Wainwright, Noel Zahr, Amit Saxena, Jill P. Buyon

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Background: Experimental and clinical evidence support the role of macrophage Toll-like receptor signaling in maternal anti-SSA/Ro–mediated congenital heart block (CHB). Objectives: Hydroxychloroquine (HCQ), an orally administered Toll-like receptor antagonist widely used in lupus including during pregnancy, was evaluated for efficacy in reducing the historical 18% recurrence rate of CHB. Methods: This multicenter, open-label, single-arm, 2-stage clinical trial was designed using Simon's optimal approach. Anti-SSA/Ro–positive mothers with a previous pregnancy complicated by CHB were recruited (n = 19 Stage 1; n = 35 Stage 2). Patients received 400 mg daily of HCQ prior to completion of gestational week 10, which was maintained through pregnancy. The primary outcome was 2° or 3° CHB any time during pregnancy, and secondary outcomes included isolated endocardial fibroelastosis, 1° CHB at birth and skin rash. Results: By intention-to-treat (ITT) analysis, 4 of 54 evaluable pregnancies resulted in a primary outcome (7.4%; 90% confidence interval: 3.4% to 15.9%). Because 9 mothers took potentially confounding medications (fluorinated glucocorticoids and/or intravenous immunoglobulin) after enrollment but prior to a primary outcome, to evaluate HCQ alone, 9 additional mothers were recruited and followed the identical protocol. In the per-protocol analysis restricted to pregnancies exposed to HCQ alone, 4 of 54 (7.4%) fetuses developed a primary outcome as in the ITT. Secondary outcomes included mild endocardial fibroelastosis (n = 1) and cutaneous neonatal lupus (n = 4). Conclusions: These prospective data support that HCQ significantly reduces the recurrence of CHB below the historical rate by >50%, suggesting that this drug should be prescribed for secondary prevention of fetal cardiac disease in anti-SSA/Ro-exposed pregnancies. (Preventive Approach to Congenital Heart Block With Hydroxychloroquine [PATCH]; NCT01379573)

Original languageEnglish (US)
Pages (from-to)292-302
Number of pages11
JournalJournal of the American College of Cardiology
Volume76
Issue number3
DOIs
StatePublished - Jul 21 2020

Keywords

  • anti-SSA/Ro antibodies
  • congenital heart block
  • hydroxychloroquine
  • neonatal lupus
  • prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers'. Together they form a unique fingerprint.

  • Cite this

    Izmirly, P., Kim, M., Friedman, D. M., Costedoat-Chalumeau, N., Clancy, R., Copel, J. A., Phoon, C. K. L., Cuneo, B. F., Cohen, R. E., Robins, K., Masson, M., Wainwright, B. J., Zahr, N., Saxena, A., & Buyon, J. P. (2020). Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. Journal of the American College of Cardiology, 76(3), 292-302. https://doi.org/10.1016/j.jacc.2020.05.045